September 15, 2025

Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes

Lung cancer patients who take medications called GLP-1 receptor agonists — commonly prescribed for weight loss and diabetes management — fare better than those who don’t, according to research.

Roswell Park Comprehensive Cancer Center

September 01, 2025

Dana-Farber Research News 09.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 - August 15.

Dana-Farber

August 22, 2025

Web Tool Seeks to Reduce State Lung Cancer Mortality Rates

Experts from the National Lung Cancer Roundtable have created a customizable, web-based platform that allows groups and local leaders to develop state-based action plans for reducing lung cancer morta...

The ASCO Post

August 22, 2025

Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations

The agent was approved by the FDA today for adults with unresectable or metastatic nonsquamous NSCLC whose tumors have HER2 tyrosine kinase domain (TKD)–activating mutations, as detected by an FDA-app...

The ASCO Post

August 22, 2025

Ultraprocessed Food Consumption May Be Linked to Increased Lung Cancer Risk

Greater consumption of ultraprocessed food may be associated with an increased risk of developing either small cell or non–small cell lung cancer, according to findings published in Thorax. 

The ASCO Post

July 24, 2025

Study Paves Path to Improved Diagnosis, Treatment of NUT Carcinoma

Dana-Farber research uncovered the potential for underdiagnosis of this aggressive cancer and identified additional tests required for an accurate diagnosis.

Dana-Farber

February 17, 2023

Study Finds Neoadjuvant Nivolumab Led to Improved 5-Year Survival Outcomes in Patients With Resectable NSCLC

The results from a 5-year follow-up analysis of a small clinical trial of patients with stage I to IIIA non­–small cell lung cancer (NSCLC) who were treated with nivolumab for 4 weeks before surgery s...

The ASCO Post

February 08, 2023

Uptake of Immune Checkpoint Inhibitors and Survival Among Younger and Older Patients With Advanced NSCLC

In a U.S. cohort study reported in JAMA Oncology, Voruganti et al found that the uptake of immune checkpoint inhibitor therapy for patients with advanced non–small cell lung cancer (NSCLC) has been as...

The ASCO Post

August 09, 2023

Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial

As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit wit...

The ASCO Post